

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
06 September 2024 (06.09.2024)



(10) International Publication Number  
**WO 2024/180085 A1**

(51) International Patent Classification:  
C07K 16/22 (2006.01) A61P 15/02 (2006.01)  
(21) International Application Number:  
PCT/EP2024/054990

(22) International Filing Date:  
27 February 2024 (27.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
23305259.6 27 February 2023 (27.02.2023) EP

(71) Applicants: **NETRIS PHARMA** [FR/FR]; 28 rue Laennec Centre Léon Bérard, 69008 LYON (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel Ange, 75016 PARIS (FR). **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE** [FR/FR]; 101, Rue de Tolbiac, 75013 PARIS (FR). **CENTRE LEON BERARD** [FR/FR]; 28, rue Laennec, 69008 LYON (FR). **UNIVERSITÉ CLAUDE BERNARD LYON 1** [FR/FR]; 43, boulevard du 11 novembre 1918, 69100 VILLEURBANNE (FR). **FLINDERS UNIVERSITY** [AU/AU]; Sturt Road, BEDFORD PARK, 5042 (AU).

(72) Inventors: **MEHLEN, Patrick**; 780 Route de Nivolas, 38300 SEREZIN-DE-LA-TOUR (FR). **BERNET, Agnès**; 780 route de Nivolas, 38300 SEREZIN DE LA TOUR (FR). **DUCAROUGE, Benjamin**; 12 Rue des Bruyères, 38110 LA TOUR DU PIN (FR). **CASTRO KRAFTCHENKO, Joel**; 9A Lanark Avenue, Seaton, ADELAIDE, South Australia 5023 (AU). **BRIERLEY, Stuart**; 19 Stanfield Avenue, Windsor Gardens, ADELAIDE, South Australia 5087 (AU). **MADDERN, Jessica Elizabeth**; 20 Hallmark Court Mount Barker, ADELAIDE, South Australia 5251 (AU).

(74) Agent: **GRAND, Guillaume** et al.; LAVOIX, 62 rue de Bonnel, 69448 LYON Cedex 03 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2024/180085 A1

(54) Title: ANTI-NETRIN-1 MONOCLONAL ANTIBODY FOR TREATING ENDOMETRIOSIS AND ASSOCIATED PAINS

(57) Abstract: The invention concerns the treatment of endometriosis using an anti-netrin- 1 antibody or an antigen-binding fragment thereof, and such antibody or fragment thereof for use in treating endometriosis. Said treating comprises a reduction of the endometriosis lesions, especially the uterine and/or uterine horn endometriosis lesions. Said treating further comprises a chronic pelvic pain relief or vaginal hyperalgesia relief. It may also comprise a reduction of colorectal hyperalgesia developed in endometriosis, an improvement of bladder dysfunction developed in endometriosis, a reduction of enhanced cutaneous sensitivity to thermal and/or mechanical stimuli developed in endometriosis, an improvement of the overall wellbeing altered by the endometriosis.